Published in Blood on October 06, 2010
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 2.11
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood (2011) 1.58
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood (2013) 1.54
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant (2012) 1.28
How I treat late effects in adults after allogeneic stem cell transplantation. Blood (2010) 1.26
Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant (2014) 1.15
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol (2013) 1.13
Delivering care to long-term adult survivors of hematopoietic cell transplantation. J Clin Oncol (2012) 1.01
Granulocyte colony-stimulating factor-producing esophageal squamous cell carcinoma following chemoradiotherapy and bone marrow transplantation for acute lymphoblastic leukemia. Esophagus (2013) 0.93
Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. Haematologica (2015) 0.91
Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression. Biol Blood Marrow Transplant (2013) 0.88
Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report. Biol Blood Marrow Transplant (2016) 0.87
Subsequent malignant neoplasms after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2012) 0.87
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter (2012) 0.86
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther (2012) 0.86
Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant (2015) 0.86
Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant (2012) 0.84
Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research. Biol Blood Marrow Transplant (2012) 0.83
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia (2016) 0.81
Decreased mental health care utilization following a psychosocial intervention in caregivers of hematopoietic stem cell transplant patients. Ment Illn (2014) 0.79
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biol Blood Marrow Transplant (2016) 0.79
Clinical approach in the management of oral chronic graft-versus-host disease (cGVHD) in a series of specialized medical centers. Support Care Cancer (2014) 0.79
Use of azathioprine for graft-vs-host disease is the major risk for development of secondary malignancies after haematopoietic stem cell transplantation: a nationwide population-based study. Br J Cancer (2014) 0.79
Effects of conditioning regimens and T cell depletion in hematopoietic cell transplantation for primary immune deficiency. Biol Blood Marrow Transplant (2012) 0.78
Long-term follow-up after allogeneic stem cell transplantation. Dtsch Arztebl Int (2015) 0.75
Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care. Biol Blood Marrow Transplant (2016) 0.75
Esophageal intramucosal hematoma after peripheral blood stem cell transplantation: case report and review of literature. Int J Clin Exp Pathol (2014) 0.75
Glioblastoma Multiforme in a Post Allogeneic Stem Cell Transplant Patient. A Case Report and Literature Review of Post Transplant Neurological Tumors. Indian J Hematol Blood Transfus (2015) 0.75
p53 phosphorylation and TP53 copy-number alterations in chronic graft-versus-host oral lichen preceding squamous cell carcinoma. J Invest Dermatol (2013) 0.75
Adherence to cancer screening guidelines in Australian survivors of allogeneic blood and marrow transplantation (BMT). Cancer Med (2016) 0.75
Cellular transplant therapies for globoid cell leukodystrophy: Preclinical and clinical observations. J Neurosci Res (2016) 0.75
Risk Factors for Subsequent Central Nervous System (CNS) Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant (HCT): a Study From the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant (2017) 0.75
Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ (1987) 27.11
Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med (1999) 5.82
Quantification of the completeness of follow-up. Lancet (2002) 4.77
Solid cancers after bone marrow transplantation. N Engl J Med (1997) 4.62
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant (2006) 2.93
Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet (1998) 2.87
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst (2002) 2.44
Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer (2005) 2.30
New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol (2003) 2.19
Elementary methods of cohort analysis. Int J Epidemiol (1984) 2.15
Solid cancers after bone marrow transplantation. J Clin Oncol (2001) 1.99
New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol (2000) 1.92
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2006) 1.87
Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood (2005) 1.73
Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med (1999) 1.59
Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol (2006) 1.42
Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res (2006) 1.31
Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol (2009) 1.29
Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood (2007) 1.22
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res (2006) 1.13
Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol (2007) 1.07
Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer (2007) 1.01
Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation? Clin Cancer Res (2009) 0.96
Granulocyte-macrophage-colony stimulating factor stimulates tumor invasiveness in squamous cell lung carcinoma. Cancer (1998) 0.89
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis (2011) 9.37
Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med (2004) 7.10
Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet (2007) 6.93
Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med (2012) 6.30
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis (2010) 5.53
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol (2010) 4.67
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis (2006) 4.42
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res (2009) 4.24
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood (2003) 4.15
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 3.65
Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron (2004) 3.61
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood (2002) 3.56
One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med (2014) 3.07
Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood (2011) 3.02
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis (2011) 2.89
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol (2011) 2.78
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) (2011) 2.77
miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res (2010) 2.75
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood (2009) 2.73
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med (2014) 2.69
Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol (2012) 2.68
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood (2011) 2.66
miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells (2009) 2.64
Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One (2010) 2.63
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant (2007) 2.60
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res (2010) 2.50
Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol (2011) 2.49
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood (2007) 2.36
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol (2011) 2.31
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood (2003) 2.31
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant (2006) 2.24
Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett (2011) 2.24
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood (2002) 2.14
Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood (2013) 2.12
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 2.11
Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers (Basel) (2011) 2.10
Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease. Blood (2002) 2.08
Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood (2011) 2.03
Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant (2003) 2.03
Multi-targeted therapy of cancer by genistein. Cancer Lett (2008) 2.02
Impending challenges in the hematopoietic stem cell transplantation physician workforce. Biol Blood Marrow Transplant (2009) 1.97
The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood (2007) 1.96
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood (2009) 1.96
Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem (2011) 1.94
Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol (2005) 1.93
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol (2013) 1.88
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2006) 1.87
Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. Blood (2010) 1.85
Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One (2011) 1.82
Pharmacological characterization of human and murine neuropeptide s receptor variants. J Pharmacol Exp Ther (2005) 1.81
Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res (2011) 1.80
Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica (2008) 1.80
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells (2008) 1.78
A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis (2002) 1.77
Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr Transplant (2007) 1.76
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2012) 1.74